天津医药 ›› 2020, Vol. 48 ›› Issue (12): 1244-1248.doi: 10.11958/20200333

• 综述 • 上一篇    

新型生物标志物TMAO与心血管疾病关系的研究进展

王洁1,高静2△   

  1. 1天津医科大学胸科临床学院(邮编300222);2天津市胸科医院心血管病研究所
  • 收稿日期:2020-03-02 修回日期:2020-08-31 出版日期:2020-12-15 发布日期:2020-12-13
  • 通讯作者: 高静 E-mail:gaojing2088@163.com
  • 作者简介:王洁(1993),女,硕士研究生在读,主要从事心血管疾病的临床研究
  • 基金资助:
    天津市卫生行业重点攻关项目(16KG131);天津市科技重大专项与工程项目(16ZXMJSY00150)

Research progress on the relationship between TMAO of new biomarkers and #br# cardiovascular diseases#br#

WANG Jie1, GAO Jing2△   

  1. 1 Clinical College of Chest, Tianjin Medical University, Tianjin 300222, China;
    2 Institute of Cardiovascular Disease, Tianjin Chest Hospital
  • Received:2020-03-02 Revised:2020-08-31 Published:2020-12-15 Online:2020-12-13
  • Contact: GAO Jing E-mail:gaojing2088@163.com

摘要: 肠道菌群及其代谢产物与心血管疾病的关系是心血管领域研究的热点,有关探索肠道菌群在调节心血管生理和疾病进展中作用的基础与临床研究已取得了较大进展。国内外一些研究表明肠道微生物源代谢物三甲胺-N-氧化物(TMAO)已经成为影响心血管疾病发生发展的一个关键因素。近年来TMAO与心血管疾病的发生发展及预后关系的临床研究也取得了一些成果,血浆TMAO水平未来可作为心血管疾病危险分层、诊断及预后的新型生物标志物,对心血管疾病的发生和主要心血管事件(MACE)进行预测。本文就TMAO作为心血管疾病新型生物标志物及潜在治疗靶点的研究进展进行综述。

关键词: 胃肠道微生物组, 动脉粥样硬化, 心血管疾病, 三甲胺-N-氧化物

Abstract: The relationship between gut microbiota and its metabolites and cardiovascular disease is a hot topic in cardiovascular research. It has made great progress in the basic and clinical research of gut microbiota in regulating cardiovascular physiology and disease progress. Some studies at home and abroad have shown that metabolite trimethylamine-N-oxide (TMAO), the gut microbiota, has become a key factor affecting the development of cardiovascular disease. In recent years, clinical studies on the relationship between TMAO and development and prognosis of cardiovascular diseases have also made some achievements. Plasma TMAO levels can be used as new biomarkers for the risk stratification, diagnosis and prognosis of cardiovascular diseases in the future, and the prediction of the occurrence of cardiovascular disease and the major cardiovascular events (MACE). This paper reviews the research progress of TMAO as a new biomarker and potential therapeutic target for cardiovascular diseases.

Key words: gastrointestinal microbiome, atherosclerosis, cardiovascular diseases, trimethylamine-N-oxide (TMAO)

中图分类号: